BioSpace News Archive

The opportunity to do interesting and meaningful work continues to be more valuable than money, according to more than 2,700 life science professionals who took BioSpace’s 2019 Ideal Employer survey.

Following Purdue Pharma’s Chapter 11 filing last month, other opioid makers are exploring ways to settle their own litigation problems by participating in the OxyContin drugmaker’s bankruptcy proceedings.

The tips that follow will help you make the most of your relationship with recruiters, also known as headhunters and search firms.

Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China.

Sareum Holdings plc is pleased to announce that it will present new preclinical data from its SDC-1802 TYK2/JAK1 inhibitor cancer research programme at the American Association for Cancer Research National Cancer Institute European Organisation for Research and Treatment of Cancer International Conference, to be held 26-30 October 2019 in Boston, USA.

IntelGenx Corp., a leader in pharmaceutical films, announced that it has resubmitted its 505 New Drug Application for RIZAPORT® VersaFilm® for the treatment of acute migraines to the U.S. Food and Drug Administration.

C4X Discovery Holdings plc is pleased to note Indivior PLC’s announcement that the National Institutes of Health has granted Indivior’s application entitled “Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder” pursuant to Funding Opportunity Announcement RFA-DA-19-002 dedicated to the development of medications to prevent and treat opioid use disorder and overdose.

Responses observed in patients with microsatellite stable (MSS) colorectal cancer, a disease not historically sensitive to checkpoint inhibition

Centauri Therapeutics, an immunotherapy company active in oncology and infectious diseases, announces that it will attend the following scientific and investor conferences

Novo Seeds, the company creation team of Novo Holdings, announced that it has co-led the €20 million Series A financing round in STipe Therapeutics (STipe).